Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)

Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system

(2018) Jane A Mitchell et al.   BRITISH JOURNAL OF PHARMACOLOGY

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement

(2016) Kirsten Bibbins-Domingo et al.   ANNALS OF INTERNAL MEDICINE

Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery DiseaseClinical Perspective

(2016) Francesco Franchi et al.   CIRCULATION

A Critical Appraisal of Aspirin in Secondary Prevention

(2016) Giuseppe Gargiulo et al.   CIRCULATION

Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1

(2016) Francesca Rauzi et al.   FASEB JOURNAL

A brief review on the mechanisms of aspirin resistance

(2016) Gang Du et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Aspirin and Cancer

(2016) Paola Patrignani et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy

(2016) Timothy D. Warner et al.   Expert Review of Hematology

Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells

(2016) Paloma Guillem-Llobat et al.   Oncotarget

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer

(2016) Yin Cao et al.   JAMA Oncology

The role of epoxyeicosatrienoic acids in the cardiovascular system

(2015) L. Yang et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Inherited human group IVA cytosolic phospholipase A2 deficiency abolishes platelet, endothelial, and leucocyte eicosanoid generation

(2015) Nicholas S. Kirkby et al.   FASEB JOURNAL

Comparison of Aggregometry with Flow Cytometry for the Assessment of Agonists´-Induced Platelet Reactivity in Patients on Dual Antiplatelet Therapy

(2015) Thomas Gremmel et al.   PLoS One

Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease

(2015) Eitan A. Friedman et al.   THROMBOSIS RESEARCH

Estimates of benefits and harms of prophylactic use of aspirin in the general population

(2014) J. Cuzick et al.   ANNALS OF ONCOLOGY

Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay

(2014) M. Lordkipanidze et al.   BLOOD

Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice

(2014) G. Ortiz-Munoz et al.   BLOOD

2014 ESC/EACTS Guidelines on myocardial revascularization

(2014)   EUROPEAN HEART JOURNAL

Analysis, physiological and clinical significance of 12-HETE: A neglected platelet-derived 12-lipoxygenase product

(2014) Benedetta Porro et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

12-hydroxyeicosatetraenoic acid is associated with variability in aspirin-induced platelet inhibition

(2014) Benjamin H Maskrey et al.   Journal of Inflammation-London

Maresin 1 biosynthesis during platelet–neutrophil interactions is organ-protective

(2014) Raja-Elie E. Abdulnour et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin

(2013) J Etulain et al.   BRITISH JOURNAL OF PHARMACOLOGY

Tailored antiplatelet therapy and clinical adverse outcomes

(2013) Jiabei Li et al.   HEART

Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation

(2013) Maceler Aldrovandi et al.   JOURNAL OF LIPID RESEARCH

Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding

(2013) Udaya S. Tantry et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

(2013)   LANCET

High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition

(2013) Jan-Arne Björkman et al.   THROMBOSIS RESEARCH

Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist

(2012) Brendan J. Whittle et al.   BIOCHEMICAL PHARMACOLOGY

Prostacyclin Receptor Regulation --- from Transcription to Trafficking

(2012) C. Midgett et al.   CURRENT MOLECULAR MEDICINE

Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome

(2012) James P. Smith et al.   HYPERTENSION

Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays

(2012) L. CONSUEGRA-SÁNCHEZ et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials

(2012) Peter M Rothwell et al.   LANCET

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

(2012) Annemijn M Algra et al.   LANCET ONCOLOGY

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

(2012) Jean-Philippe Collet et al.   NEW ENGLAND JOURNAL OF MEDICINE

PGE2reverses Gs-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-Gs-mediated inhibition of platelet aggregation by interaction with EP4 receptors

(2012) Jacqueline R. Glenn et al.   PLATELETS

Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system

(2012) N. S. Kirkby et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice

(2012) Y. Yu et al.   Science Translational Medicine

Clinical Outcomes Using a Platelet Function-Guided Approach for Secondary Prevention in Patients With Ischemic Stroke or Transient Ischemic Attack

(2012) Jeremiah P. Depta et al.   STROKE

Five-Year Analysis of the Prevention of Colorectal Sporadic Adenomatous Polyps Trial

(2011) Nadir Arber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Applications of Mass Spectrometry to Lipids and Membranes

(2011) Richard Harkewicz et al.   Annual Review of Biochemistry

Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy

(2011) Timothy D. Warner et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial

(2011) Kenneth W. Mahaffey et al.   CIRCULATION

Antiplatelet agents for the treatment and prevention of atherothrombosis

(2011) Carlo Patrono et al.   EUROPEAN HEART JOURNAL

Antiplatelet effects of aspirin vary with level of P2Y12 receptor blockade supplied by either ticagrelor or prasugrel

(2011) N. S. KIRKBY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation

(2011) T. ULRYCH et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

(2011) John Burn et al.   LANCET

Incomplete inhibition of platelet function as assessed by the platelet function analyzer (PFA-100) identifies a subset of cardiovascular patients with high residual platelet response while on aspirin

(2011) M. Crescente et al.   PLATELETS

Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing

(2011) Melissa V. Chan et al.   PLATELETS

Thromboxane and the thromboxane receptor in cardiovascular disease

(2010) Emer M Smyth   Clinical Lipidology

Epoxyeicosatrienoic Acid Analogs and Vascular Function

(2010) V. Sudhahar et al.   CURRENT MEDICINAL CHEMISTRY

Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?

(2010) T. D. Warner et al.   HEART

Serum Thromboxane B2 Compared to Five Other Platelet Function Tests for the Evaluation of Aspirin Effect in Stable Cardiovascular Disease

(2010) Giselle Kidson-Gerber et al.   Heart Lung and Circulation

Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors

(2010) G. Petrucci et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation

(2010) P. C. J. ARMSTRONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

(2010) Peter M Rothwell et al.   LANCET

Antagonism of P2Y12reduces physiological thromboxane levels

(2010) Kamala Bhavaraju et al.   PLATELETS

Role of Antiplatelet Therapy Across the Spectrum of Patients with Coronary Artery Disease

(2009) Deepak L. Bhatt   AMERICAN JOURNAL OF CARDIOLOGY

Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays

(2009) Francesca Santilli et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials

(2009) Bernard F. Cole et al.   JNCI-Journal of the National Cancer Institute

Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy

(2009) P. C. J. ARMSTRONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone

(2008) Chiara Bolego et al.   FASEB JOURNAL

Use of the PFA-100™ closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis

(2008) J.-L. RENY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Aspirin and thein vitrolinear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2

(2008) P. C. J. ARMSTRONG et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

(2008) John A Baron et al.   LANCET

Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome

(2008) John Burn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rebuttal to "Aspirin response variability assessed with the PFA-100 device" by Reny et al.

(2008) Marilena Crescente et al.   THROMBOSIS AND HAEMOSTASIS

PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients

(2008) Marilena Crescente et al.   THROMBOSIS AND HAEMOSTASIS

Maintaining Equilibrium by Selective Targeting of Cyclooxygenase Pathways

(2007) Ruba S. Deeb et al.   HYPERTENSION